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Objectives: To compare the efﬁcacy and safety of a novel dry powder formulation of
inhaled colistimethate sodium, Colobreathe®, versus tobramycin nebuliser solution
(TNS) in an open-label multi-center, randomised study.
Methods: 380 subjects (aged 6 years) from 66 CF centres in EU countries, Russia
and Ukraine were randomized to Colobreathe® 125mg twice daily or TNS 300mg
twice daily. The primary endpoint was non-inferiority of Colobreathe® for change
in FEV1% predicted after 24 weeks, pre-speciﬁed -3%. Secondary endpoints were
changes in antibiotic resistance and the safety and convenience of Colobreathe®,
using a quality of life (QoL) questionnaire.
Colobreathe® was as safe and as well tolerated as TNS in adult and paediatric
subjects with CF. After logarithmic transformation based on non-normal value
distribution, the adjusted mean difference between Colobreathe® and TNS groups in
the change in FEV1% predicted at week 24 was −0.97% (95%CI: −2.74%, 0.86%)
for the ITT population(n = 374), while it was −0.56% (95%CI: −2.71%, 1.70%) for
the PP population(n = 261). In the Colobreathe® and TNS groups, the proportion
of colistin-resistant isolates during the 24-week period was low (1.1%) compared
to 11.0–19.7% of tobramycin resistant isolates. At week 24, the QoL assessments
were in favour of Colobreathe® in ITT and PP populations.
Conclusions: Colobreathe® demonstrated non-inferiority to TNS in lung function
over 24 week treatment and CF subjects favoured Colobreathe® over TNS. We
conclude that Colobreathe is as effective and was similarly tolerated as TNS in the
management of chronic P. aeruginosa infection in CF.
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Objective: EDIT (Establish tobramycin Dry powder effIcacy in cysTic ﬁbrosis;
NCT00918957) was conducted to conﬁrm the efﬁcacy of tobramycin inhalation
powder (TIP) produced with a modiﬁed manufacturing process.
Methods: A randomized, double-blind trial of a single cycle of 28 days on/28 days
off treatment with twice-daily TIP 112mg or placebo in patients with cystic ﬁbrosis
and Pseudomonas aeruginosa (Pa) lung infection, aged 6−21 years, and naive to
inhaled anti-pseudomonal therapy (at least for past 4 months). Primary endpoint
was relative change in mean FEV1% predicted from baseline to Day 29. Other
assessments included change in sputum Pa density, safety and tolerability.
Results: 62 patients were randomized (n = 32 TIP, n = 30 placebo), falling short of
the planned target of 100. Mean treatment differences (TIP-placebo) for relative and
absolute change in FEV1% predicted were 5.9% (p = 0.148) and 4.4% (p = 0.0496)
respectively. Statistical signiﬁcance for the primary endpoint was achieved in
sensitivity analyses when excluding an outlier patient and when excluding invalid
screening spirometry measures. TIP signiﬁcantly decreased Pa sputum density by
1.2 log10 colony forming units vs placebo (p = 0.002). TIP was well tolerated with
a safety proﬁle consistent with previous ﬁndings.
Conclusion: Placebo control and use of treatment-naive patients led to signiﬁcant
recruitment challenges and an underpowered study. However, EDIT demonstrates
TIP to be effective in improving lung function and reducing Pa bacterial load.
